Company intelligence / Profile preview

Beijing Tide Pharmaceutical Co., Ltd.

Beijing, Beijing, China

Ownership: Private
Employees: ~180
Development stage: Phase 1

Overview

The company has multiple approved products including Flurbiprofen Axetil Injection and Alprostadil. Their innovative drug TDI01 for COVID-19 was approved for clinical trials in September 2022 and has completed Phase I trials in the US with good safety results. The company also has products in Phase 3 trials for diabetic peripheral neuropathic pain and osteoarthritis.

Therapeutic areas: PulmonologyOncologyRheumatologyGastroenterologyCardiovascularNeurologyInfectious Diseases
Modalities: Small moleculesBiologicsEnzymeAntibody fusion proteinsChemical drugsBiosimilar
Industry: Biotech

Drug pipeline

12 assets

TDI01

11 more assets in the full pipeline.

Request access →

Partnerships

Mikasa Seiyaku Co., Ltd.American company for tricuspid valve repairJapanese pharmaceutical companies (OEM)

Beyond the preview

Go deeper on Beijing Tide Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Tide Pharmaceutical Co., Ltd..

Explore the full profile